Ultragenyx Pharmaceutical Inc. [RARE] stock prices are up 7.62% to $57.05 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The RARE shares have gain 10.22% over the last week, with a monthly amount glided 26.27%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Ultragenyx Pharmaceutical Inc. [NASDAQ: RARE] stock has seen the most recent analyst activity on June 06, 2024, when Goldman upgraded its rating to a Buy and also boosted its price target to $67 from $56. Previously, RBC Capital Mkts started tracking the stock with Outperform rating on April 22, 2024, and set its price target to $77. On December 08, 2023, Wells Fargo initiated with a Overweight rating and assigned a price target of $72 on the stock. Evercore ISI upgraded its rating to a Outperform and raised its price target to $80 on June 06, 2023. Cantor Fitzgerald started tracking with a Overweight rating for this stock on April 26, 2023, and assigned it a price target of $114.
The stock price of Ultragenyx Pharmaceutical Inc. [RARE] has been fluctuating between $31.52 and $54.56 over the past year. Currently, Wall Street analysts expect the stock to reach $108.14 within the next 12 months. Ultragenyx Pharmaceutical Inc. [NASDAQ: RARE] shares were valued at $57.05 at the most recent close of the market. An investor can expect a potential return of 89.55% based on the average RARE price forecast.
Analyzing the RARE fundamentals
The Ultragenyx Pharmaceutical Inc. [NASDAQ:RARE] reported sales of 481.30M for trailing twelve months, representing a surge of 35.75%. Gross Profit Margin for this corporation currently stands at 0.83% with Operating Profit Margin at -1.14%, Pretax Profit Margin comes in at -1.22%, and Net Profit Margin reading is -1.22%. To continue investigating profitability, this company’s Return on Assets is posted at -0.36, Equity is -2.66 and Total Capital is -0.41. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 54.46 points at the first support level, and at 51.86 for the second support level. However, for the 1st resistance point, the stock is sitting at 58.37, and for the 2nd resistance point, it is at 59.68.
Ratios To Look Out For
It’s worth pointing out that Ultragenyx Pharmaceutical Inc. [NASDAQ:RARE]’s Current Ratio is 3.54. On the other hand, the Quick Ratio is 3.39, and the Cash Ratio is 1.78. Considering the valuation of this stock, the price to sales ratio is 10.93, the price to book ratio is 12.15.
Transactions by insiders
Recent insider trading involved KAKKIS EMIL D, President & CEO, that happened on Aug 06 ’24 when 20000.0 shares were sold. Officer, KAKKIS EMIL D completed a deal on Aug 06 ’24 to buy 20000.0 shares. Meanwhile, Director Sanders Corazon (Corsee) D. sold 584.0 shares on Jul 02 ’24.
